nnd is the Expert in Lung Function Testing at the Point of Care

Diffusion capacity (DLCO) is the most powerful predictor of survival in COPD patients.¹

**Why DLCO?**

To predict severe exacerbations in COPD that would likely result in hospitalization or ER visit⁴

To monitor patients with drug induced pulmonary toxicity³

Differential diagnosis between asthma and emphysema²

To detect interstitial lung disease early, before spirometry and lung volumes become decreased²
EasyOne Pro® provides the most efficient and accurate way to test lung function in any setting. Engineered using our patented TrueFlow™ and TrueCheck™ technology, the EasyOne Pro® eliminates all sources of error, saves time and gives your patients the best pulmonary care in your practice or lung function lab.

DLCO testing adds only 5 minutes to spirometry and doubles reimbursement

Instant interpretation of results with the ATS/ERS decision tree

Bringing the diagnosis closer to the patient with point of care testing

Proven worldwide: NIH, COPDGene, GOLD, NASA, World Trade Center

All clinical statements come from these sources:
COPDGene, DLCO Influences Morbidity Beyond Spirometry and CT Evidence of Emphysema in COPDGene, May 2018¹
ATS/ERS, Interpretative strategies for lung function tests, April 2005²
Consultant360, Using and Interpreting Carbon Monoxide Diffusing Capacity (Dlco) Correctly, May 2016¹
CHEST, Diffusing Capacity of Carbon Monoxide i Assessment of COPD, Oct 2019³